LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
LUIS GONZAGA PAZ-ARES RODRÍGUEZ-rekin lankidetzan egindako argitalpenak (35)
2024
-
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
The Lancet Regional Health - Europe, Vol. 38
-
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
-
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium
Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362
2023
-
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562
-
Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 10.1007/s12094-022-03046-9)
Clinical and Translational Oncology
-
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1252-1267
-
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 56, Núm. 2, pp. 97-112
2022
-
Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy
Journal of Clinical Medicine, Vol. 11, Núm. 6
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
Tumor mutational burden assessment in non-small-cell lung cancer samples: Results from the TMB 2 harmonization project comparing three NGS panels
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5
2020
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2018
-
Aligning digital CD8
+
scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma
Histopathology, Vol. 72, Núm. 2, pp. 270-284
-
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
Oncologist, Vol. 23, Núm. 9, pp. 1092-1102
2017
-
A consensus statement on the gender perspective in lung cancer
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535
-
Biological therapies in nonsmall cell lung cancer
European Respiratory Journal, Vol. 49, Núm. 3
-
Treating KRAS -mutant NSCLC: Latest evidence and clinical consequences
Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 9, pp. 589-597